Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Phase 3 Recruiting 355 enrolled Sun Pharmaceutical Industries, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Timeline

Start: 2025-08-05
Primary completion: 2028-05
Completion: 2028-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTP-543	Unknown	8 mg	Oral

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Summary

Timeline

Drugs

Indications